Jacques Theurillat

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom.